Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Kidney International

• Publication date

  2014-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/ki.2013.465PMID 24336032
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Living donor age and kidney transplant outcomes: an assessment of risk across the age continuum

  2013cited by this paper
• Renal function following living, standard criteria deceased and expanded criteria deceased donor kidney transplantation: impact on graft failure and death

  2012cited by this paper
• Kidney Function and Risk of Cardiovascular Disease and Mortality in Kidney Transplant Recipients: The FAVORIT Trial

  2012cited by this paper
• Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody‐Mediated Rejection and Nonadherence

  2012cited by this paper
• Randomized trial of immunosuppressive regimens in renal transplantation.

  2011cited by this paper
• Long‐Term Renal Allograft Survival in the United States: A Critical Reappraisal

  2011cited by this paper
• Monitoring Nonadherence and Acute Rejection With Variation in Blood Immunosuppressant Levels in Pediatric Renal Transplantation

  2011cited by this paper
• Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children

  2010cited by this paper
• High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation.

  2010cited by this paper
• Identifying Specific Causes of Kidney Allograft Loss

  2009cited by this paper
• Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus

  2009cited by this paper
• Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients

  2008cited by this paper
• Reduced exposure to calcineurin inhibitors in renal transplantation.

  2008cited by this paper
• Evaluating non‐adherence to immunosuppressant medications in pediatric liver transplant recipients

  2008cited by this paper
• Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result.

  2008cited by this paper
• Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions

  2008cited by this paper
• [The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies].

  2008cited by this paper
• Nonadherence Consensus Conference Summary Report

  2008cited by this paper
• An objective measure to identify pediatric liver transplant recipients at risk for late allograft rejection related to non‐adherence

  2008cited by this paper
• Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient.

  2007cited by this paper
• The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies

  2007cited by this paper
• The importance of transitions between dialysis and transplantation in the care of end-stage renal disease patients.

  2007cited by this paper
• Reduced exposure to calcineurin inhibitors in renal transplantation.

  2007cited by this paper
• The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies

  2007cited by this paper
• Banff '05 Meeting Report: Differential Diagnosis of Chronic Allograft Injury and Elimination of Chronic Allograft Nephropathy (‘CAN’)

  2007cited by this paper
• Relationships of tacrolimus pharmacokinetic measures and adverse outcomes in stable adult liver transplant recipients

  2006cited by this paper
• Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data

  2005cited by this paper
• Illustrating the Impact of a Time-Varying Covariate With an Extended Kaplan-Meier Estimator

  2005cited by this paper
• Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials1

  2004cited by this paper
• Long‐Term Renal Allograft Survival: Have we Made Significant Progress or is it Time to Rethink our Analytic and Therapeutic Strategies?

  2004cited by this paper
• Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients.

  2004cited by this paper
• THE RATE OF GASTRIC EMPTYING DETERMINES THE TIMING BUT NOT THE EXTENT OF ORAL TACROLIMUS ABSORPTION: SIMULTANEOUS MEASUREMENT OF DRUG EXPOSURE AND GASTRIC EMPTYING BY CARBON-14-OCTANOIC ACID BREATH TEST IN STABLE RENAL ALLOGRAFT RECIPIENTS

  2004cited by this paper
• Tacrolimus: a further update of its use in the management of organ transplantation.

  2003cited by this paper
• Drug Interactions with Tacrolimus

  2002cited by this paper
• Death After Graft Loss: An Important Late Study Endpoint in Kidney Transplantation

  2002cited by this paper
• Drug interactions with tacrolimus.

  2002cited by this paper
• The changing causes of graft loss and death after kidney transplantation

  2002cited by this paper
• Tacrolimus trough level adjustment after administration of fluconazole to kidney recipients.

  2002cited by this paper
• The Banff 97 working classification of renal allograft pathology.

  1999cited by this paper
• The use of fractional polynomials to model continuous risk variables in epidemiology.

  1999cited by this paper
• Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: multivariate analyses from the United States Renal Data System.

  1998cited by this paper
• The Effect of Antilymphocyte Induction Therapy on Renal Allograft Survival

  1998cited by this paper
• Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis.

  1997cited by this paper
• Logical and statistical fallacies in the use of Cox regression models.

  1996cited by this paper
• Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability.

  1995cited by this paper
• Long-term benefits and risks of cyclosporin A (sandimmun)--an analysis at 10 years.

  1994cited by this paper

• CNI Trough Variability Does Not Reliably Reflect Medication Adherence: Insights From a 3-Year Follow-Up Study

  2026cites this paper
• Tacrolimus intrapatient variability and rejection are associated with inferior allograft outcomes after kidney transplantation

  2025cites this paper
• Tacrolimus Exposure is Associated with Acute Rejection in the Early Phase After Kidney Transplantation: A Joint Modeling Approach

  2025cites this paper
• The Number of Episodes of Subtherapeutic Tacrolimus Blood Level Is Independently Associated With Reduced Kidney Graft Survival

  2024influential citation
• Immunosuppressant nonadherence profile in kidney transplant recipients and the impact of medication adherence on transplant outcomes

  2024cites this paper
• Long-Term Outcomes with Prolonged-Release Tacrolimus in Kidney Transplantation: A Retrospective Real-World Data Analysis

  2024cites this paper
• Immunosuppresseurs en transplantation rénale : mécanismes d’action et suivi biologique

  2024cites this paper
• Association of CYP3A4-392A/G, CYP3A5-6986A/G, and ABCB1-3435C/T Polymorphisms with Tacrolimus Dose, Serum Concentration, and Biochemical Parameters in Mexican Patients with Kidney Transplant

  2024cites this paper
• High intra-patient variability of tacrolimus within post-operative 1 month predicted worse 1-year outcomes in pediatric liver transplant recipients

  2024cites this paper
• Tacrolimus intra-patient variability measures and its associations with allograft clinical outcomes in kidney transplantation.

  2024cites this paper
• Cannabis use is associated with reduced access to kidney transplantation and an increased risk of acute rejection post‐transplant

  2024cites this paper
• A Randomized Controlled Trial of Envarsus Versus Immediate Release Tacrolimus in Kidney Transplant Recipients With Delayed Graft Function.

  2023cites this paper
• Association of high intra-patient variability in tacrolimus exposure with calcineurin inhibitor nephrotoxicity in kidney transplantation

  2023cites this paper
• Non-Traditional Non-Immunological Risk Factors for Kidney Allograft Loss—Opinion

  2023cites this paper
• A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based Bayesian Prediction.

  2023cites this paper
• Impact of tacrolimus intra-patient variability in adverse outcomes after organ transplantation

  2023cites this paper
• The Importance Of Avoiding Time-Dependent Bias When Testing The Prognostic Value Of An Intervening Event - Two Acute Cellular Rejection Examples In Intestinal Transplantation.

  2023cites this paper
• Tacrolimus Trough Level Variation and Its Correlation to Clinical Outcomes and Consequences in Solid Organ Transplantation

  2023cites this paper
• Effect of Jejunal Administration on Tacrolimus Trough Concentrations in a Pediatric Liver Transplant Recipient.

  2022cites this paper
• Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers

  2022cites this paper
• Tacrolimus Formulation, Exposure Variability, and Outcomes in Kidney Transplant Recipients

  2022cites this paper
• Exposure to tacrolimus trough levels below 6 ng/ml during the first year is associated with inferior kidney graft survival

  2022cites this paper
• Comparison of Tacrolimus Intra-Patient Variability during 6–12 Months after Kidney Transplantation between CYP3A5 Expressers and Nonexpressers

  2022cites this paper
• Lower Time in Therapeutic Range Relates to a Worse Kidney Graft Outcome.

  2022cites this paper
• Pharmacotherapeutic options for the prevention of kidney transplant rejection: the evidence to date

  2022influential citation
• Detecting, preventing and treating non-adherence to immunosuppression after kidney transplantation

  2022cites this paper
• Association of intraindividual tacrolimus variability with de novo donor-specific HLA antibody development and allograft rejection in pediatric kidney transplant recipients with low immunological risk

  2022cites this paper
• Time within therapeutic range: A comparison of three tacrolimus formulations in renal transplant recipients

  2022cites this paper
• Impacto de la variabilidad intrapaciente en la concentración sanguínea de anticalcineurínicos en los resultados del trasplante cardiaco

  2021cites this paper
• A new method to calculate intra‐patient variability in tacrolimus concentrations

  2021cites this paper
• FK506-loaded PLGA nanoparticles improve long-term survival of a vascularized composite allograft in a murine model

  2021cites this paper
• Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation

  2021cites this paper
• Intrapatient Variability in Tacrolimus Trough Levels Over 2 Years Affects Long-Term Allograft Outcomes of Kidney Transplantation

  2021cites this paper
• Effect of glecaprevir/pibrentasvir on weight‐adjusted tacrolimus trough/dose ratios in heart and kidney transplant recipients

  2021cites this paper
• Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation.

  2021cites this paper
• Clinical Implications of Tacrolimus Time in Therapeutic Range and Intrapatient Variability in Urban Renal Transplant Recipients Undergoing Early Corticosteroid Withdrawal

  2021cites this paper
• Prospective Measures of Adherence by Questionnaire, Low Immunosuppression and Graft Outcome in Kidney Transplantation

  2021cites this paper
• Dynamic prediction based on variability of a longitudinal biomarker

  2021cites this paper
• A new method to calculate intra‐patient variability in tacrolimus concentrations

  2021cites this paper
• Tacrolimus variability score outperforms coefficient of variation in predicting clinical outcomes of living kidney transplantation

  2021cites this paper
• Therapies for Chronic Allograft Rejection

  2021cites this paper
• BK Polyomavirus Nephropathy in Kidney Transplantation: Balancing Rejection and Infection

  2021cites this paper
• Remote intervention engagement and outcomes in the Clinical Trials in Organ Transplantation in Children consortium multisite trial

  2021cites this paper
• Impact of intrapatient blood level variability of calcineurin inhibitors on heart transplant outcomes.

  2021cites this paper
• Adoption of a novel smart mobile‐health application technology to track chronic immunosuppression adherence in solid organ transplantation: Results of a prospective, observational, multicentre, pilot study

  2021cites this paper
• Adherence to Pharmacotherapy and Lifestyle Recommendations Among Hemodialyzed Patients and Kidney Transplant Recipients.

  2021cites this paper
• Transplant regimen adherence for kidney recipients by engaging information technologies (TAKE IT): Rationale and methods for a randomized controlled trial of a strategy to promote medication adherence among transplant recipients.

  2021cites this paper
• Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients

  2021cites this paper
• Early Monitoring and Subsequent Gain of Tacrolimus Time-In-Therapeutic Range May Improve Clinical Outcomes After Living Kidney Transplantation

  2021cites this paper
• Posttraumatic stress and medication adherence in pediatric transplant recipients

  2021cites this paper
• A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients

  2021cites this paper
• Maintenance Immunosuppression in Solid Organ Transplantation: Integrating Novel Pharmacodynamic Biomarkers to Inform Calcineurin Inhibitor Dose Selection

  2020cites this paper
• Ten-Year Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant: A Prospective Cohort Study.

  2020cites this paper
• A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation

  2020cites this paper
• Effect of CYP3A4*22 and CYP3A4*1B but not CYP3A5*3 polymorphisms on tacrolimus pharmacokinetic model in Tunisian kidney transplant.

  2020cites this paper
• Exploratory Analysis of the Impact of an mHealth Medication Adherence Intervention on Tacrolimus Trough Concentration Variability: Post Hoc Results of a Randomized Controlled Trial

  2020cites this paper
• High Intrapatient Variability in Tacrolimus Exposure Calculated Over a Long Period Is Associated With De Novo Donor-Specific Antibody Development and/or Late Rejection in Thai Kidney Transplant Patients Receiving Concomitant CYP3A4/5 Inhibitors

  2020cites this paper
• Analyses of AUC(0–12) and C0 Compliances within Therapeutic Ranges in Kidney Recipients Receiving Cyclosporine or Tacrolimus

  2020cites this paper
• Monitoring Tacrolimus Trough Concentrations During the First Year After Kidney Transplantation: A National Retrospective Cohort Study

  2020cites this paper
• Tacrolimus intrapatient variability in solid organ transplantation: A multiorgan perspective

  2020cites this paper
• Donor Specific Anti-HLA Antibodies in Kidney Transplantation

  2020influential citation
• Blood Profiles of Gut Bacterial Tacrolimus Metabolite in Kidney Transplant Recipients

  2020cites this paper
• The Effects of Intrapatient Variability in Tacrolimus Concentration on Clinical Outcomes Immediately After Liver Transplantation

  2020cites this paper
• CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.

  2020influential citation
• Dosing algorithm for Tacrolimus in Tunisian Kidney transplant patients: Effect of CYP 3A4*1B and CYP3A4*22 polymorphisms.

  2020cites this paper
• No Apparent Influence of Non-Adherence on Tacrolimus Intra-Patient Variability in Stable Kidney Transplant Recipients.

  2020cites this paper
• Association of graft survival with tacrolimus exposure and late intra‐patient tacrolimus variability in pediatric and young adult renal transplant recipients—an international CTS registry analysis

  2020cites this paper
• Evidence for the alloimmune basis and prognostic significance of Borderline T cell–mediated rejection

  2020cites this paper
• Appreciating the Impact of Tacrolimus Sampling Time Deviations in Pediatric Patients with Nephrotic Syndrome.

  2020cites this paper
• The TOMATO Study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the Concentration–Dose Ratio on Death-censored Graft Survival

  2020cites this paper
• Monitoring of Donor-specific Anti-HLA Antibodies and Management of Immunosuppression in Kidney Transplant Recipients: An Evidence-based Expert Paper.

  2020cites this paper
• Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients

  2020cites this paper
• Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives

  2020cites this paper
• THIRTY YEARS OF TACROLIMUS IN CLINICAL PRACTICE.

  2020cites this paper
• Tacrolimus Intra-Patient Variability, Time in Therapeutic Range, and Risk of De Novo Donor-Specific Antibodies.

  2020cites this paper
• Effect on Dosage Change and Intrapatient Variability After Conversion From Twice-Daily to Once-Daily Tacrolimus Among Thai Kidney Transplant Patients With and Without CYP3A4/5 Inhibitors.

  2019cites this paper
• Development and future deployment of a 5 years allograft survival model for kidney transplantation

  2019cites this paper
• Incidence of Donor-Specific Anti-HLA Antibodies in Non-HLA-Sensitized Patients Given Tacrolimus Once or Twice Daily During the First 2 Years After Kidney Transplant.

  2019cites this paper
• Reduction of exposure to tacrolimus trough level variability is associated with better graft survival after kidney transplantation

  2019cites this paper
• Routine adherence monitoring after renal transplantation

  2019cites this paper
• Evaluation of tools for annual capture of adherence to immunosuppressive medications after renal transplantation – a single‐centre open prospective trial

  2019cites this paper
• High Intra-Patient Variability in Tacrolimus Exposure Is Not Associated with Immune-Mediated Graft Injury after Liver Transplantation.

  2019cites this paper
• Late intra‐patient tacrolimus trough level variability as a major problem in kidney transplantation: A Collaborative Transplant Study Report

  2019cites this paper
• High Calcineurin Inhibitor Intrapatient Variability Is Associated With Renal Allograft Inflammation, Chronicity, and Graft Loss

  2019cites this paper
• Evaluation of Clinical and Safety Outcomes Following Uncontrolled Tacrolimus Conversion in Adult Transplant Recipients

  2019cites this paper
• An update on the safety of tacrolimus in kidney transplant recipients, with a focus on tacrolimus minimization

  2019cites this paper
• Comparative pharmacokinetics of tacrolimus in stable pediatric allograft recipients converted from immediate‐release tacrolimus to prolonged‐release tacrolimus formulation

  2019cites this paper
• Comparison of Transplant Outcomes for Low-level and Standard-level Tacrolimus at Different Time Points after Kidney Transplantation

  2019cites this paper
• Real-World Study of Once-Daily, Extended-Release Tacrolimus Versus Twice-Daily, Immediate-Release Tacrolimus in Kidney Transplantation: Clinical Outcomes and Healthcare Resource Utilization

  2019cites this paper
• Safety and Efficacy of Reduced Prolonged-release Tacrolimus Exposure in De Novo Kidney Transplantation: A Randomized, Open-label, Pilot Study in Asia—OPTIMIZE Study

  2019cites this paper
• Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report

  2019cites this paper
• A Novel, Dose-Adjusted Tacrolimus Trough-Concentration Model for Predicting and Estimating Variance After Kidney Transplantation

  2019cites this paper
• Association of Intrapatient Variability of Tacrolimus Concentration With Early Deterioration of Chronic Histologic Lesions in Kidney Transplantation

  2019cites this paper
• Long-Term Outcomes after Acute Rejection in Kidney Transplant Recipients: An ANZDATA Analysis.

  2019cites this paper
• Non-linear relationship between tacrolimus blood concentration and acute rejection after kidney transplantation: a systematic review and dose-response meta-analysis of cohort studies.

  2019cites this paper
• Relevance of donor‐specific antibody monitoring after kidney transplantation: Findings from the Collaborative Transplant Study and the Heidelberg Transplant Center

  2019cites this paper
• Model based development of tacrolimus dosing algorithm considering CYP3A5 genotypes and mycophenolate mofetil drug interaction in stable kidney transplant recipients

  2019cites this paper
• Intrapatient Variability of Tacrolimus Exposure in Solid Organ Transplantation: A Novel Marker for Clinical Outcome

  2019cites this paper
• Medication non-adherence after kidney transplantation: A critical appraisal and systematic review.

  2019cites this paper
• Identification of Antibiotic Administration as a Potentially Novel Factor Associated With Tacrolimus Trough Variability in Kidney Transplant Recipients: A Preliminary Study

  2019cites this paper